GENEVA — Lung cancer researchers continue to be excited over the potential for immunotherapy, and the subject was given a top billing here in a keynote lecture on the first day of the European Lung ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results